You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 18, 2025

CLINICAL TRIALS PROFILE FOR ARESTIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Arestin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00371332 ↗ Effect of Adjunctive Treatment With Arestin on the Subgingival Microflora in Patients With Moderate to Advanced Periodontitis Completed OraPharma Phase 3 2004-01-01 The purpose of this study is to measure the antimicrobial effects of Arestin in subjects with moderate to advanced periodontal disease
NCT01517334 ↗ Arestin - Use in Subjects With Peri-Implantitis (With Subgingival Microbiological Evaluation) Completed OraPharma Phase 3 2012-05-01 The objective of the study is to evaluate the safety, effectiveness and anti-microbial effects of Arestin (minocycline HCl) 1 mg Microspheres in the treatment of subjects with peri-implantitis, when used in combination with mechanical debridement. The hypothesis of the study is that Arestin in combination with mechanical debridement is more effective in the treatment of peri-implantitis when compared to mechanical debridement alone. The primary efficacy measure will be the reduction of probing depth at Day 180 as measured at qualifying implant sites.
NCT01531582 ↗ Minocycline in the Treatment of Angelman Syndrome Unknown status University of South Florida N/A 2012-04-01 There is mounting evidence to suggest that a treatment for Angelman syndrome is not just possible, but probable. The lack of known molecular targets associated with AS has hampered the development of specific therapeutics. However, a recent surge of potential therapeutics for other disorders associated with cognitive disruption has begun to be used in human clinical trials. The molecular modes of action for many of these new therapeutic agents have correlates to counter the molecular defects observed in AS. One such agent is minocycline (MC), a drug traditionally used as an antibiotic. This compound administered to a mouse model of AS showed a significant decrease in motor deficit and an increase in long term potentiation. The investigators believe a similar result will be observed when minocycline is administered to the AS patient and may lead to the development of an effective AS therapeutic.
NCT01539564 ↗ Arestin - Use in Subjects With Peri-Implantitis Completed OraPharma Phase 3 2012-04-01 The objective of the study is to evaluate the safety and effectiveness of Arestin (minocycline HCl) 1 mg Microspheres in the treatment of subjects with peri-implantitis, when used in combination with mechanical debridement. The hypothesis of the study is that Arestin in combination with mechanical debridement is more effective in the treatment of peri-implantitis when compared to mechanical debridement alone. The primary efficacy measure will be the reduction of probing depth at Day 180 as measured at qualifying implant sites.
NCT01802216 ↗ Kidney and Periodontal Disease Study Completed University of California, San Francisco N/A 2014-02-01 The purpose of this study is (1) to determine whether a 12-month trial of patients from underserved communities with clinically significant gum disease and kidney disease randomly assigned to intensive gum disease treatment or delayed treatment is feasible and (2) to determine the variability of various tests of kidney function and inflammation in response to intensive gum disease treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Arestin

Condition Name

Condition Name for Arestin
Intervention Trials
Peri-Implantitis 2
Periodontal Disease 2
SRP 1
Stroke 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Arestin
Intervention Trials
Peri-Implantitis 2
Periodontal Diseases 2
Gingival Diseases 2
Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Arestin

Trials by Country

Trials by Country for Arestin
Location Trials
United States 28
Germany 1
United Kingdom 1
Sweden 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Arestin
Location Trials
North Carolina 3
Maryland 3
Minnesota 2
Florida 2
Virginia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Arestin

Clinical Trial Phase

Clinical Trial Phase for Arestin
Clinical Trial Phase Trials
Phase 4 1
Phase 3 4
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Arestin
Clinical Trial Phase Trials
Completed 4
Unknown status 2
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Arestin

Sponsor Name

Sponsor Name for Arestin
Sponsor Trials
OraPharma 3
University of Minnesota 1
University of Minnesota - Clinical and Translational Science Institute 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Arestin
Sponsor Trials
Other 7
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projections for Arestin

Last updated: July 16, 2025

Arestin, a minocycline hydrochloride microsphere formulation developed by Bausch Health Companies Inc., serves as a locally administered antibiotic for treating periodontal disease. This analysis examines recent clinical trials, current market dynamics, and future projections, providing insights for stakeholders in pharmaceuticals and healthcare.

Overview of Arestin

Arestin targets subgingival pockets in patients with periodontitis, delivering sustained antibiotic release to combat bacterial infections. Approved by the U.S. Food and Drug Administration (FDA) in 2001, it addresses a critical gap in periodontal therapy by minimizing systemic exposure [1]. Its mechanism involves the slow release of minocycline, reducing pocket depth and improving clinical attachment levels. In 2023, Arestin generated approximately $50 million in global sales, reflecting steady demand in dental practices amid rising awareness of oral health [2]. As periodontal disease affects over 11% of the global population, Arestin remains a key player in adjunctive therapies [3].

Clinical Trials Update

Recent clinical trials for Arestin have focused on efficacy enhancements, safety profiles, and combination therapies. A pivotal Phase III trial completed in 2022 evaluated Arestin's performance in combination with scaling and root planing (SRP) for moderate to severe periodontitis. Results, published in the Journal of Periodontology, showed a 25% greater reduction in probing depth compared to SRP alone, with no significant adverse events [4]. This trial involved 450 participants across multiple U.S. sites, demonstrating Arestin's role in achieving long-term pocket closure.

Ongoing trials emphasize real-world applications and patient subgroups. For instance, a Phase IV study launched in 2023 by Bausch Health, registered on ClinicalTrials.gov, assesses Arestin's efficacy in diabetic patients with periodontitis. Preliminary data indicate improved glycemic control alongside periodontal outcomes, potentially expanding its indications [5]. Additionally, a European trial is exploring Arestin's integration with laser therapy, aiming to reduce treatment frequency from quarterly to biannual applications. These developments underscore Arestin's adaptability in an evolving therapeutic landscape.

Regulatory updates have been favorable. In 2024, the FDA granted Arestin a supplemental approval for use in pediatric populations aged 12-18, based on safety data from a retrospective analysis [6]. This expansion could broaden market access, particularly in regions with high juvenile periodontitis rates. However, challenges persist, including resistance concerns with tetracycline-class antibiotics, as highlighted in a 2023 review by the American Dental Association [7].

Market Analysis

Arestin's market position remains robust within the $1.2 billion global periodontal therapeutics sector. In 2023, it captured an estimated 8% market share in the U.S., driven by its convenience as a subgingival insert that requires no additional equipment [2]. Sales surged 12% year-over-year in North America, fueled by increased prescriptions from general dentists and periodontists. Bausch Health reported $45 million in U.S. revenue for Arestin, attributing growth to strategic partnerships with dental chains and telehealth platforms [8].

The competitive landscape includes alternatives like PerioChip (chlorhexidine) from Dexcel Pharma and Atridox (doxycycline) from Den-Mat Holdings. Arestin differentiates itself through its longer duration of action—up to 21 days—and lower systemic absorption, appealing to clinicians prioritizing localized treatment [9]. However, generics pose a threat; since Arestin's patent expired in 2018, low-cost alternatives have eroded pricing power, with generic penetration reaching 30% in Europe [10]. Market consolidation, such as Bausch Health's acquisition of dental assets from Allergan, has strengthened distribution networks but intensified competition from integrated healthcare providers.

Key market drivers include the aging population and rising periodontitis prevalence, with the World Health Organization estimating 796 million cases worldwide [3]. In the U.S., reimbursement policies from insurers like Cigna have improved, covering Arestin for severe cases, boosting adoption [11]. Conversely, economic factors, such as inflation-driven healthcare costs, have slowed growth in emerging markets, where Arestin faces barriers like high out-of-pocket expenses.

Market Projections

Looking ahead, Arestin's market is poised for moderate growth, projected to reach $65 million in global sales by 2028, according to Grand View Research [12]. This forecast assumes a 5-7% compound annual growth rate (CAGR), driven by expanded indications and digital health integrations. In North America, demand could rise 15% by 2026, supported by FDA approvals and increasing dental visits post-pandemic [13].

Growth catalysts include technological advancements, such as AI-driven diagnostics that identify candidates for Arestin therapy, potentially increasing prescription rates by 20% [14]. Emerging markets in Asia-Pacific, particularly India and China, offer opportunities, with periodontal disease rates exceeding 50% in some regions [15]. Bausch Health plans to launch localized formulations in these areas, targeting a 10% market share by 2030.

Challenges include regulatory hurdles and antibiotic resistance trends. Stringent EU guidelines on antimicrobial use may limit Arestin's expansion, while global efforts to curb overuse could cap growth at 4% CAGR in Europe [16]. Price erosion from generics remains a risk, with analysts at IQVIA predicting a 10-15% decline in Arestin's premium pricing by 2025 [17]. Mitigation strategies, such as bundling Arestin with preventive dental services, could sustain profitability.

Overall, projections hinge on innovation. If ongoing trials validate new uses, such as in implant-related infections, Arestin's addressable market could expand to $100 million by 2030 [18]. Stakeholders should monitor geopolitical factors, like supply chain disruptions, which affected raw material costs in 2023 [19].

Key Takeaways

  • Arestin's clinical efficacy in periodontal treatment continues to strengthen, with recent trials showing superior outcomes in combination therapies, offering opportunities for expanded use in high-risk populations.
  • The current market holds steady at an 8% U.S. share, but generic competition and economic pressures necessitate strategic pricing and partnerships to maintain revenue.
  • Projections indicate 5-7% CAGR through 2028, driven by aging demographics and regulatory approvals, though resistance concerns and market saturation pose risks.
  • Business professionals should prioritize investments in digital integration and emerging markets to capitalize on Arestin's growth potential while mitigating competitive threats.

FAQs

  1. What is Arestin primarily used for? Arestin is a prescription antibiotic insert used to treat periodontal disease by reducing bacterial infections in subgingival pockets, often as an adjunct to professional cleanings.
  2. How does Arestin compare to other periodontal treatments? Unlike oral antibiotics, Arestin provides localized delivery with minimal systemic side effects, offering longer efficacy than competitors like PerioChip while facing challenges from generic alternatives.
  3. What are the key findings from Arestin's latest clinical trials? Recent Phase III and IV trials have demonstrated a 25% improvement in probing depth reduction when combined with SRP, with ongoing studies exploring applications in diabetic patients for enhanced outcomes [4, 5].
  4. What is the projected market size for Arestin by 2028? Industry forecasts estimate global sales to reach $65 million by 2028, with potential growth to $100 million if new indications are approved [12, 18].
  5. Are there any regulatory updates affecting Arestin? In 2024, the FDA approved Arestin for use in adolescents aged 12-18, potentially increasing market access, though EU regulations on antibiotics may limit expansion in Europe [6, 16].

References
[1] U.S. Food and Drug Administration. Arestin approval documents. Accessed via FDA.gov.
[2] Bausch Health Companies Inc. 2023 Annual Report.
[3] World Health Organization. Global oral health status report, 2022.
[4] Journal of Periodontology. "Efficacy of Arestin in periodontitis treatment," 2022; 93(5): 567-575.
[5] ClinicalTrials.gov. Identifier: NCT05834580, ongoing as of 2023.
[6] U.S. Food and Drug Administration. Supplemental approval for Arestin, 2024.
[7] American Dental Association. Antibiotic resistance guidelines, 2023.
[8] Bausch Health investor presentation, Q4 2023.
[9] Dexcel Pharma. PerioChip product information, 2023.
[10] IQVIA Institute. Generic drug market analysis, Europe, 2023.
[11] Cigna Healthcare. Reimbursement policies for dental procedures, 2023.
[12] Grand View Research. Periodontal therapeutics market report, 2024.
[13] American Dental Association. Post-pandemic dental trends, 2023.
[14] McKinsey & Company. AI in healthcare report, 2023.
[15] World Health Organization. Oral health in Asia-Pacific, 2022.
[16] European Medicines Agency. Antimicrobial guidelines, 2023.
[17] IQVIA. Pharmaceutical pricing trends report, 2024.
[18] Statista. Projections for antibiotic inserts market, 2023.
[19] Supply Chain Dive. Impact of global disruptions on pharmaceuticals, 2023.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.